.. .. Un-peu-d'histoire, , pp.25-26

.. .. Système,

. .. Epidémiologie, , pp.27-28

. .. , Présentation clinique, évolution naturelle et démarche diagnostique des gliomes, vol.28, p.30

. Prise-en-charge-thérapeutique and . .. Suivi,

. .. Taux-de-survie, 31-34 2.2.1.1 Vitesse ou pente de croissance tumorale, pp.33-34

. Facteurs and .. .. De-la-biopsie-ou-chirurgie-d'exerese-tumorale,

. .. Tep)-et-gliomes, , pp.36-42

. Principes-généraux,-radiotraceurs-intéressant-en-neuro-oncologie and T. .. Indications, 3.1.4 TEP aux analogues nucléosidiques : 18 F-FLT, pp.36-39

.. .. Tep-À-la-18-f-fdopa-en-pratique, 40 3.2.2 Préparation des patients, modalités d'acquisition

. .. Objectif-de-l'étude,

. Conclusion and . .. Perspectives,

. , Discussion des résultats et comparaison avec la littérature, pp.56-57

.. .. Principales, , pp.57-58

. .. Conclusion,

. .. Bibliographie, , pp.60-64

R. De and L. T. ,

Q. T. Ostrom, H. Gittleman, P. Farah, A. Ondracek, Y. Chen et al., CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010, Neuro-Oncol, vol.15, issue.2, pp.1-56, 2013.

M. L. Bondy, M. E. Scheurer, B. Malmer, J. S. Barnholtz-sloan, F. G. Davis et al., Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer, vol.113, pp.1953-68, 2008.

B. A. Kohler, E. Ward, B. J. Mccarthy, M. J. Schymura, L. Ries et al., Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system, J Natl Cancer Inst, vol.103, issue.9, pp.714-750, 2011.

N. L. Jansen, V. Graute, L. Armbruster, B. Suchorska, J. Lutz et al., MRIsuspected low-grade glioma: is there a need to perform dynamic FET PET?, Eur J Nucl Med Mol Imaging. juin, vol.39, issue.6, pp.1021-1030, 2012.

D. N. Louis, H. Ohgaki, O. D. Wiestler, W. K. Cavenee, P. C. Burger et al., The 2007 WHO classification of tumours of the central nervous system, Acta Neuropathol (Berl). août, vol.114, issue.2, pp.97-109, 2007.

D. N. Louis, A. Perry, G. Reifenberger, V. Deimling, A. Figarella-branger et al., The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary, Acta Neuropathol (Berl). juin, vol.131, issue.6, pp.803-823, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01479018

J. Pallud, D. Fontaine, H. Duffau, E. Mandonnet, N. Sanai et al., Natural history of incidental World Health Organization grade II gliomas, Ann Neurol, vol.68, issue.5, pp.727-760, 2010.

J. Pallud, E. Mandonnet, H. Duffau, M. Kujas, R. Guillevin et al., Prognostic value of initial magnetic resonance imaging growth rates for World Health Organization grade II gliomas, Ann Neurol. sept, vol.60, issue.3, pp.380-383, 2006.
URL : https://hal.archives-ouvertes.fr/inserm-00163977

J. Pallud, M. Blonski, E. Mandonnet, E. Audureau, D. Fontaine et al., Velocity of tumor spontaneous expansion predicts long-term outcomes for diffuse low-grade gliomas, Neuro-Oncol. mai, vol.15, issue.5, pp.595-606, 2013.

E. Mandonnet, J. Delattre, M. Tanguy, K. R. Swanson, A. F. Carpentier et al., Continuous growth of mean tumor diameter in a subset of grade II gliomas, Ann Neurol. avr, vol.53, issue.4, pp.524-532, 2003.

C. Gozé, M. Blonski, L. Maistre, G. Bauchet, L. Dezamis et al., Imaging growth and isocitrate dehydrogenase 1 mutation are independent predictors for diffuse lowgrade gliomas, Neuro-Oncol. août, vol.16, issue.8, pp.1100-1109, 2014.

D. Galanaud, F. Nicoli, D. Figarella-branger, P. Roche, S. Confort-gouny et al.,

, J Radiol. juin, vol.87, issue.6, pp.822-854, 2006.

A. Laprie, I. Catalaa, E. Cassol, T. R. Mcknight, D. Berchery et al., Proton magnetic resonance spectroscopic imaging in newly diagnosed glioblastoma: predictive value for the site of postradiotherapy relapse in a prospective longitudinal study, Int J Radiat Oncol Biol Phys. 1 mars, vol.70, issue.3, pp.773-81, 2008.

H. Ohgaki and P. Kleihues, Genetic alterations and signaling pathways in the evolution of gliomas, Cancer Sci. déc, vol.100, issue.12, pp.2235-2276, 2009.

Y. Kim, S. Nobusawa, M. Mittelbronn, W. Paulus, B. Brokinkel et al., Molecular classification of low-grade diffuse gliomas, Am J Pathol. déc, vol.177, issue.6, pp.2708-2722, 2010.

P. Metellus, B. Coulibaly, C. Colin, A. M. De-paula, A. Vasiljevic et al., Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis, Acta Neuropathol (Berl). déc, vol.120, issue.6, pp.719-748, 2010.
URL : https://hal.archives-ouvertes.fr/hal-01848106

M. J. Van-den-bent, H. J. Dubbink, Y. Marie, A. A. Brandes, M. Taphoorn et al., IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group, Clin Cancer Res Off J Am Assoc Cancer Res. 1 mars, vol.16, issue.5, pp.1597-604, 2010.

C. Houillier, X. Wang, G. Kaloshi, K. Mokhtari, R. Guillevin et al., IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas, Neurology, vol.75, issue.17, pp.1560-1566, 2010.

M. Sanson, Y. Marie, S. Paris, A. Idbaih, J. Laffaire et al., Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas, J Clin Oncol Off J Am Soc Clin Oncol. 1 sept, vol.27, issue.25, pp.4150-4154, 2009.

H. Broholm, P. W. Born, D. Guterbaum, H. Dyrbye, and H. Laursen, Detecting chromosomal alterations at 1p and 19q by FISH and DNA fragment analysis-a comparative study in human gliomas, Clin Neuropathol. déc, vol.27, issue.6, pp.378-87, 2008.

G. Cairncross, B. Berkey, E. Shaw, R. Jenkins, and B. Scheithauer, Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402, J Clin Oncol Off J Am Soc Clin Oncol. 20 juin, vol.9402, issue.18, pp.2707-2721, 2006.
DOI : 10.1200/jco.2005.04.3414

URL : http://www.brainlife.org/reprint/2006/cairncross_g060620.pdf

A. Peraud, F. W. Kreth, O. D. Wiestler, P. Kleihues, and H. Reulen, Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas, Clin Cancer Res Off J Am Assoc Cancer Res. mai, vol.8, issue.5, pp.1117-1141, 2002.

M. Huncharek and B. Kupelnick, Epidermal growth factor receptor gene amplification as a prognostic marker in glioblastoma multiforme: results of a meta-analysis, Oncol Res, vol.12, issue.2, pp.107-119, 2000.

W. Chen, Clinical applications of PET in brain tumors, J Nucl Med Off Publ Soc Nucl Med. sept, vol.48, issue.9, pp.1468-81, 2007.

A. M. Omuro, C. C. Leite, K. Mokhtari, and J. Delattre, Pitfalls in the diagnosis of brain tumours, Lancet Neurol. nov, vol.5, issue.11, pp.937-985, 2006.

K. Herholz, Brain Tumors: An Update on Clinical PET Research in Gliomas, Semin Nucl Med. janv, vol.47, issue.1, pp.5-17, 2017.
DOI : 10.1053/j.semnuclmed.2016.09.004

T. Singhal, T. K. Narayanan, V. Jain, J. Mukherjee, and J. Mantil, 11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas, Mol Imaging Biol MIB Off Publ Acad Mol Imaging. févr, vol.10, issue.1, pp.1-18, 2008.

M. Kinoshita, T. Goto, H. Arita, Y. Okita, K. Isohashi et al., Imaging 18 Ffluorodeoxy glucose/ 11 C-methionine uptake decoupling for identification of tumor cell infiltration in peritumoral brain edema, J Neurooncol. janv, vol.106, issue.2, pp.417-442, 2012.

R. Bergmann, J. Pietzsch, F. Fuechtner, B. Pawelke, B. Beuthien-baumann et al., 3-O-methyl-6-18F-fluoro-L-dopa, a new tumor imaging agent: investigation of transport mechanism in vitro, J Nucl Med Off Publ Soc Nucl Med. déc, vol.45, issue.12, pp.2116-2138, 2004.

C. Schiepers, W. Chen, T. Cloughesy, M. Dahlbom, and S. Huang, 18F-FDOPA kinetics in brain tumors, J Nucl Med Off Publ Soc Nucl Med, vol.48, issue.10, pp.1651-61, 2007.
DOI : 10.2967/jnumed.106.039321

URL : http://jnm.snmjournals.org/content/48/10/1651.full.pdf

A. Becherer, G. Karanikas, M. Szabó, G. Zettinig, S. Asenbaum et al., Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine, Eur J Nucl Med Mol Imaging. nov, vol.30, issue.11, pp.1561-1568, 2003.
DOI : 10.1007/s00259-003-1259-1

B. J. Fueger, J. Czernin, T. Cloughesy, D. H. Silverman, C. L. Geist et al., Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas, J Nucl Med Off Publ Soc Nucl Med, vol.51, issue.10, pp.1532-1540, 2010.
DOI : 10.2967/jnumed.110.078592

URL : http://jnm.snmjournals.org/content/51/10/1532.full.pdf

L. Janvier, P. Olivier, M. Blonski, O. Morel, J. Vignaud et al., Correlation of SUV-Derived Indices With Tumoral Aggressiveness of Gliomas in Static 18F-FDOPA PET: Use in Clinical Practice, Clin Nucl Med. sept, vol.40, issue.9, pp.429-435, 2015.

J. Schwarzenberg, J. Czernin, T. F. Cloughesy, B. M. Ellingson, W. B. Pope et al., Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy, Clin Cancer Res Off J Am Assoc Cancer Res. 1 juill, vol.20, issue.13, pp.3550-3559, 2014.
DOI : 10.1158/1078-0432.ccr-13-1440

URL : http://clincancerres.aacrjournals.org/content/20/13/3550.full.pdf

A. Verger, P. Metellus, Q. Sala, C. Colin, E. Bialecki et al., IDH mutation is paradoxically associated with higher (18)F-FDOPA PET uptake in diffuse grade II and grade III gliomas, Eur J Nucl Med Mol Imaging. 14 mars, 2017.
DOI : 10.1007/s00259-017-3668-6

URL : https://hal.archives-ouvertes.fr/hal-01735109

O. Togao, A. Hiwatashi, K. Yamashita, K. Kikuchi, J. Keupp et al., Grading diffuse gliomas without intense contrast enhancement by amide proton transfer MR imaging: comparisons with diffusion-and perfusion-weighted imaging, Eur Radiol. févr, vol.27, issue.2, pp.578-88, 2017.
DOI : 10.1007/s00330-016-4328-0

F. W. Floeth, D. Pauleit, M. Sabel, G. Stoffels, G. Reifenberger et al., Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma, J Nucl Med Off Publ Soc Nucl Med. avr, vol.48, issue.4, pp.519-546, 2007.
DOI : 10.2967/jnumed.106.037895

URL : http://jnm.snmjournals.org/content/48/4/519.full.pdf

F. W. Floeth, D. Pauleit, H. Wittsack, K. J. Langen, G. Reifenberger et al., Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18F]fluoroethyl-L-tyrosine and magnetic resonance spectroscopy, J Neurosurg. févr, vol.102, issue.2, pp.318-345, 2005.
DOI : 10.3171/jns.2005.102.2.0318

U. Roelcke, M. T. Wyss, M. Nowosielski, R. Rudà, P. Roth et al., Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas, Neuro-oncology. mai, vol.18, issue.5, pp.744-51, 2016.
DOI : 10.1093/neuonc/nov282

URL : https://academic.oup.com/neuro-oncology/article-pdf/18/5/744/6881318/nov282.pdf

L. M. Cher, C. Murone, N. Lawrentschuk, S. Ramdave, A. Papenfuss et al., Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies, J Nucl Med Off Publ Soc Nucl Med. mars, vol.47, issue.3, pp.410-418, 2006.

Y. Yamamoto, Y. Maeda, N. Kawai, N. Kudomi, F. Aga et al., Hypoxia assessed by 18F-fluoromisonidazole positron emission tomography in newly diagnosed gliomas, Nucl Med Commun. juin, vol.33, issue.6, pp.621-626, 2012.
DOI : 10.1097/mnm.0b013e3283529984

R. Stupp, M. E. Hegi, T. Gorlia, S. C. Erridge, J. Perry et al., Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, Lancet Oncol. sept, vol.15, issue.10, pp.1100-1108, 2014.
DOI : 10.1016/s1470-2045(14)70379-1

URL : https://www.zora.uzh.ch/id/eprint/100322/1/Stupp.pdf

H. Duffau and L. Taillandier, New concepts in the management of diffuse low-grade glioma: Proposal of a multistage and individualized therapeutic approach, Neuro-Oncol. mars, vol.17, issue.3, pp.332-374, 2015.

M. I. De-la-fuente, R. J. Young, J. Rubel, M. Rosenblum, J. Tisnado et al., Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma, Neuro-Oncol. févr, vol.18, issue.2, pp.283-90, 2016.

R. Espagnet, M. C. Romano, A. Mancuso, V. Cicone, F. Napolitano et al., Multiparametric evaluation of low grade gliomas at follow-up: comparison between diffusion and perfusion MR with (18)F-FDOPA PET, Br J Radiol, vol.89, p.20160476, 1066.

C. Bund, C. Heimburger, A. Imperiale, B. Lhermitte, M. Chenard et al., FDOPA PET-CT of Nonenhancing Brain Tumors, Clin Nucl Med. avr, vol.42, issue.4, pp.250-257, 2017.
DOI : 10.1097/rlu.0000000000001540

E. Lopci, M. Riva, L. Olivari, F. Raneri, R. Soffietti et al., Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma, Eur J Nucl Med Mol Imaging. 21 janv, 2017.

C. Lapa, T. Linsenmann, C. M. Monoranu, S. Samnick, A. K. Buck et al., Comparison of the amino acid tracers 18F-FET and 18F-DOPA in high-grade glioma patients, J Nucl Med Off Publ Soc Nucl Med, vol.55, issue.10, pp.1611-1617, 2014.

C. J. Ledezma, W. Chen, V. Sai, B. Freitas, T. Cloughesy et al., 18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience, Eur J Radiol. août, vol.71, issue.2, pp.242-250, 2009.
DOI : 10.1016/j.ejrad.2008.04.018

C. Lapa, T. Linsenmann, C. M. Monoranu, S. Samnick, A. K. Buck et al., Comparison of the amino acid tracers 18F-FET and 18F-DOPA in high-grade glioma patients, J Nucl Med, vol.55, issue.10, pp.1611-1617, 2014.

C. Kratochwil, S. E. Combs, K. Leotta, A. Afshar-oromieh, S. Rieken et al., Intraindividual comparison of 18 F-FET and 18 F-DOPA in PET imaging of recurrent brain tumors, Neuro-oncology. mars, vol.16, issue.3, pp.434-474, 2014.